Aprocitentan
Aprocitentan has been studied in 7 papers since 2025: none in people yet, 7 reviews; 7 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 9, 2026: “New Drugs in the Treatment of Uncontrolled or Resistant Hypertension”.
3 new papers in 30 daysSee all 6 papers on aprocitentan
At a glance
14 trials, none about aging, 10 with no results posted.
- 14 trials, none about aging, 10 with no results posted
- 14 of 14 trials sponsored by its developers
What did studies of aprocitentan find?
4Studies of aprocitentan measured 4 outcomes, among them blood pressure, systolic blood pressure and albuminuria.
Blood pressure
downin humans2
2 studies
Blood pressure
downin humans2
Aprocitentan decreases blood pressure in humans (resistant hypertension).
“Dual endothelin receptor antagonists, particularly aprocitentan, have demonstrated significant and sustained blood pressure reduction in resistant hypertension”
Reviewresistant hypertension
New Drugs in the Treatment of Uncontrolled or Resistant Hypertension
Pharmaceuticals (Basel, Switzerland)
Aprocitentan decreases blood pressure in humans (resistant hypertension).
“In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria.”
Reviewresistant hypertension
Endothelin antagonism: a new era for resistant hypertension
Clinical kidney journal
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Aprocitentan decreases systolic blood pressure in humans (resistant hypertension; PRECISION trial).
“Aprocitentan reduced office and ambulatory systolic BP in resistant hypertension (PRECISION trial)”
Reviewresistant hypertension; PRECISION trial
American journal of cardiovascular drugs : drugs, devices, and other interventions
Albuminuria
downin humans1
1 study
Albuminuria
downin humans1
Aprocitentan decreases albuminuria in humans (resistant hypertension).
“In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria.”
Reviewresistant hypertension
Endothelin antagonism: a new era for resistant hypertension
Clinical kidney journal
Blood pressure
downin humans1
1 study
Blood pressure
downin humans1
Aprocitentan decreases blood pressure in patients with resistant arterial hypertension, including elderly and CKD.
“Aprocitentan has been shown to provide a sustained and clinically significant reduction in BP, including in elderly patients and those with CKD”
Reviewin patients with resistant arterial hypertension, including elderly and CKD
Ukrainian Therapeutical Journal
Has aprocitentan been tested in people?
0 of 14 about aging14 trials are registered, but no study of it in people has been published yet.
Approved
Mar 19, 2024Hypertension
Repurposing
Phase 3Results posted1 trial
Phase 2Results posted1 trial
Phase 1Completed1 trial
Phase 1Completed1 trial
Who is developing aprocitentan?
2 companies: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) and Idorsia Pharmaceuticals.
Trial sponsors
Company12 trialsPhase 32,615 people
Company1 trialPhase 3382 people